We are disciplined
game-changers
adopting an inclusive,
non-traditional model
We are disciplined
game-changers
adopting an inclusive,
non-traditional model
We are disciplined
game-changers
adopting an inclusive,
non-traditional model

What is Infusion 51A?

Infusion 51a is an impact investment fund backing the development of biotech-based solutions that were once a dream.

Since 2015, the fund has been allocating both financial and human capital into vetted opportunities with the potential to disrupt the life-science ecosystem and create revolutionary alternatives for people all around the world.

We lead great ideas from inception to reality.

We’re another breed of investors​

For us, our word is gold. We are determined to create solid alliances based on integrity and mutual trust. We protect our people fiercely, supporting our portfolio companies at all times and standing up for our shareholders.

We know that we cannot address all global issues, but we can do our best to make huge contributions to revolutionizing healthcare and human life experience.

Our business is our legacy and we aim to leave the world a better place than when we started! We hope you’ll join us on our mission.

What is Infusion 51A?

Infusion 51a is an impact investment fund backing the development of biotech-based solutions that were once a dream.

Since 2015, the fund has been allocating both financial and human capital into vetted opportunities with the potential to disrupt the life-science ecosystem and create revolutionary alternatives for people all around the world.

We lead great ideas from inception to reality.

We’re another breed of investors​

For us, our word is gold. We are determined to create solid alliances based on integrity and mutual trust. We protect our people fiercely, supporting our portfolio companies at all times and standing up for our shareholders.

We know that we cannot address all global issues, but we can do our best to make huge contributions to revolutionizing healthcare and human life experience.

Our business is our legacy and we aim to leave the world a better place than when we started! We hope you’ll join us on our mission.

We connect promising projects with their vital capital

A
PP
R
O
A
CH
Due Dilligence
Great market opportunities tracking through a rigorous data-driven process
Strategy
-Reduced cost on operational and administrative tasks
-Tactical execution with a strategic vision
Invest
-Financial obstacle removal
-Productivity improvement through Human Capital Investment
Support
Portfolio support
Execute
Scalable process and strategy implementation
Exit
Spotlight the portfolio companies in preparation of exit

Our game-changing DNA

1

We are adaptable but not malleable

We adapt our processes and decisions when necessary, embracing that change is inherent to moving forward; yet, under no circumstances will our ethics and culture be compromised or tread on.

4

We are proud of our uniqueness​​

We are different! We’re not afraid to say it!

Any business can chase profits and margins, but ours purposefully seeks out philanthropic opportunities in all our investments.

2

We believe in what we do​

We do our jobs with passion and dignity because entire families depend on the decisions we make today.

5

We are the possessors of a disciplined winning mentality​

We are determined, focused and never take our eyes off the prize. Our discipline and dedicated mentality is our superpower, easily observable in each and every member of our team.

3

We are resilient​

We understand no journey is without its pitfalls. We know that the only way to get where we want to be is by taking steps without apprehension and continuously learning.

Our game-changing DNA

1

We are adaptable but not malleable

We adapt our processes and decisions when necessary, embracing that change is inherent to moving forward; yet, under no circumstances will our ethics and culture be compromised or tread on.

2

We believe in what we do​​

We do our jobs with passion and dignity because entire families depend on the decisions we make today.

3

We are resilient​

We understand no journey is without its pitfalls. We know that the only way to get where we want to be is by taking steps without apprehension and continuously learning.

4

We are proud of our uniqueness​​

We are different! We’re not afraid to say it!

Any business can chase profits and margins, but ours purposefully seeks out philanthropic opportunities in all our investments.

5

We are the possessors of a disciplined winning mentality​

We are determined, focused and never take our eyes off the prize. Our discipline and dedicated mentality is our superpower, easily observable in each and every member of our team.

The world we want to create

Better patients outcomes
We dream of solutions that impact the lives of millions of patients worldwide, giving them more chances of successfully overcoming cancer.
Higher survival rate
We want to turn the odds in the favor of underfunded cancer patients and be a source of hope in a picture of despair and difficulties.
More prevention options
The best way to cure a disease is through prevention and early detection. We aim to live in a world of awareness and equal possibilities for all.
Better patients outcomes
We dream of solutions that impact the lives of millions of patients worldwide, giving them more chances of successfully overcoming cancer.
Higher survival rate
We want to turn the odds in the favor of underfunded cancer patients and be a source of hope in a picture of despair and difficulties.
More prevention options
The best way to cure a disease is through prevention and early detection. We aim to live in a world of awareness and equal possibilities for all.

Make an impact with your investment

Make an impact with your investment

Our Team

General Partners

We are living proof of what hard work can accomplish. We’ve built businesses from the ground up and successfully navigated through all kinds of challenges. Our journey has taught us not to settle for the ordinary and to always rise to the challenges of the future.

Jeff Stephens

General Partner

Global markets expert focused on key positioning and investment strategies.
Infusion 51a Co-founder and Chief Investment Officer. International Infusion Co-founder.
Managing Member of the General Partner and the Investment Advisor. Vivacitas Co-founder & Director. Former Theralink Director.

Scott VanderMeer, MBA

General Partner

Strategic investments and portfolio expansion. Infusion 51a Co-founder and Chief Financial Officer. International Infusion Co-founder. Managing Member of the General Partner and the Investment Advisor. Vivacitas Co-founder, Director & Interim CFO. Former Theralink Interim CFO.

Strategic Advisors

Our business strength is driven by the many stakeholders involved in our mission. Our strategic alliances make us powerful beyond all measure.

Chan Heng Fai

Strategic Advisor

Leading financial advisor with +40 years of experience in corporate
restructuring, with a personal portfolio of +35 companies worldwide. Game changer and unicorn maker.

Afshin Safavi, PhD.

Strategic Advisor

Doctorate in Biochemistry. Founder, consultant, board member, entrepreneur, and investor in biotechnology, pharmaceutical, animal health, technology, and healthcare-related real estate.

Founder and former CSO of BioAgilytix Labs. Worked in small and large pharmaceutical, biotechnology, and manufacturing companies, including GSK and Bayer. Councilman for Cherry Hills Village, CO

Fund and Portfolio Operations

Our diverse and experienced employees are the backbone of Infusion 51a. Each and every member of our organization brings a wealth of knowledge in their chosen fields. It’s this knowledge that enables us to do what we do, and do it well!

Brett Logan, JD

Securities Counsel

Investment management attorney with 20 years of practice focused on hedge funds, private equity funds, fund of funds, real estate funds and investment advisors.

Elise Brownell

Program Planning and Integration Director at Vivacitas Oncology

Executive Vice President of Operations and Project Management for the various pharmaceutical companies with +35 years of experience in biopharmaceutics. Founding team member of Aerovance, Inc. which garnered over $60 MUSD, and completed six clinical trials in 3.5 years.

Hamed Reyhanfard, PharmD, EMBA

Director of Fund Development

Doctorate of Pharmacy, EMBA and MSc in Biochemistry and Chemistry with focus on the drug development in cancer therapy and solid tumor. +8 years of experience in strategic business development, Sales/commercials and Medical with Johnson & Johnson, Janssen Biotech, Chimeron Bio and OnsetCapital Partners and active fundraising for pharmaceutical Start-ups and other sectors in the US, Europe and Middle East.

Hong Li, MBA

Account Manager

MBA in Business Administration and Bachelor in Pharmaceutical Engineering with experience in the Pharmaceutical Industry, public and private hospitals, and start-up environment and good command of marketing, sales, business operations, training and coaching.

Jeffrey Busch

Theralink Chairman

Successful entrepreneur and active investor in various asset classes, including medical and pharmaceutical since 1985. Current Chairman and CEO $300MM exit to GlaxoSmithKline.
Served on George Bush Sr. Administration.

Isabella Guzmán

Graphic Designer

Senior Graphic Designer with BA in Social Communication. +6 years of experience creating engaging visual experiences for recognized brands worldwide, in both printed and digital formats.

Krishn Patel

Director of Data Collection

Market research, online lead generation and data mining specialist with experience in different industries like Finance, Technology, Real Estate and Healthcare, in charge of developing new
technology tools and B2B marketing solutions.

Manuel Noriega

Director of Statistics and AI

Production Engineer, Data Scientist, Business Intelligence and Process Management Specialist
with +7 years of experience developing management solutions in large, medium and small
companies, thriving company equity growth and expansion of economic activities.

Maria Montilla

Director of Communications

Multimedia journalist with +7 years of proven work, with experience in VC and start-ups corporative communications, advertising strategy, trend spotting and forecasting and data storytelling. BA in Mass Communications and MA in Political Communication.

Marian Piñango

Community Manager

Communication, Marketing and SEO Specialist focused on written media and digital strategies. +4 years of experience working in communication departments and developing successful search engines campaigns.

Mark Suseck

Director of Vivacitas Oncology

+30 years of experience raising capital and implementing successful expansion strategies in the Biotech, Pharmaceutical, and MedTech industries. Mark has worked in large, diversified healthcare companies such as Johnson & Johnson and Sanofi S.A. and private equity and startup enterprises.

Mehrab Ajalli

Director of Strategic Growth in the MENA Region

Entrepreneur, investor and philanthropist. Co-founder of Radio Javan, growing to the world’s largest Persian radio station with over 1,000,000 listeners. 10+ years’ experience in Information Technology sales and business development. Strong believer of impact driven initiatives and community engagement.

Mick Ruxin, M.D

President, CEO and Director of Theralink Technologies

Prior Chairman, CEO and Founder of Global Med Technologies, Inc. (GLOB) serving over 30 countries on 4 continents, sold for $74M in public offering. One of the first 10 certified Medical
Review Officers in the country.

Monica Coleman, CPA

Finance Consultant

Fractional CFO at Chimeron Bio. +30 years of financial expertise with extensive experience with
cash flow optimization, budget creation and administration, due diligence, contract
negotiations, P&L accountability and ERP

Peter Seperack, PhD, JD

Director at Intellectual Property at Vivacitas Oncology

Ph.D. in Cellular and Developmental Biology. +30 years as a biopharmaceutical researcher and as a Biotech patent attorney. Developer of various molecular medicine breakthroughs,
including the discovery of molecular mechanism of a murine coat color mutation.

Todd Smith, MBA

Chief Commercial Officer

Senior pharmaceutical executive and board member with +25 years of medical device and
biotechnology leadership and long track record of building companies and achieving commercial and business development excellence. Current President and CEO of Assertio, Director for Vault Nano and Board Member at BVI Medical.

William Mann

Senior Associate of Capital Expansion

Scientific and Medical Advisors

Our consultants are globally recognized industry veterans whose experience spans up to four decades, serving as a source of unsurpassed wisdom and strategic thinking.

Amir Baluch, MD

Medical Advisor

BS Biochemistry. Experience physician and investor Member of the Forbes Dallas Business
Council. Best Selling Author, Investing and Passive Income Consultant. Former BioWise Capital
Biotech Hedge Fund Manager.

Bill Coleman

Scientific Advisor

PhD in Biochemestry. Executive Officer at American Society for Investigative Pathology. +20 years of experience as a professor in the University of North Carolina, both in the Department of Pathology and Laboratory Medicine and as a director of Graduate Studies, Molecular and
Cellular Pathology Graduate Program.

Cory Hogue, MD

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which look even slightly believable. If you are going to use a passage of Lorem Ipsum, you need to be sure there is anything embarrassing hidden in the middle of text. All the Lorem Ipsum generators on the Internet tend to repeat predefined chunks as necessary, making this the first true generator on the Internet. It uses a dictionary of over 200 Latin words, combined with a handful of model sentence structures, to generate Lorem Ipsum which looks reasonable. The generated Lorem Ipsum is therefore always free from repetition, injected humour, or non-characteristic words etc.Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source.

David Mahvi, MD, FACS

Medical Advisor

Internationally acclaimed healthcare executive, surgeon, and medical engineering expert with 25+ years of experience. Former Chair of the American Board of Surgery. Author of 100+ academic articles on cancer-related topics.

Emmanuel Petricoin, PhD

Scientific Advisor​

PhD. In Microbiology. Professor & Co-Director of the Center for Applied Proteomics and
Molecular Medicine (CAPMM) at George Mason University. Co-founder of 4 life science
companies in the nanotechnology diagnostic and precision medicine space. Co-authored nearly
400 publications, and is a co-inventor on 40 filed and published patents.

Justin Davis, PhD

Laboratory Director at Theralink Technologies

Ph.D. in Biochemistry. Research Assistant Professor at the Center for Applied Proteomics and Molecular Medicine focused on the RPPA technology and protein signaling, with publications spanning topics of glioblastoma tumor heterogeneity and evolving RPPA technology and its
applications.

Paul Manley, BSc

Regulatory Advisor

40+ years business expertise; 30+ years in Regulatory Affairs and Drug Development across a range of therapeutic areas in small and large pharma, Due Diligence for new or expanded
ventures specialist. Former Vice President, Global Oncology Regulatory Affairs at Johnson & Johnson. Current President & Principal Consultant at Orvieto Consulting, LLC.

Stefan Proniuk PhD, MBA

Product Development Advisor

PhD in Pharmaceutical Sciences. MBA in Entrepreneurship. Pharmaceutical Executive with 20+ years of industry experience. Leading clinical development programs from drug discovery to
commercialization. Current Chief Development Officer at Neuraptive Therapeutics.

Still have questions?

Still have questions?